Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

“…The placebo-controlled study conducted by Saad et al [12] shows zoledronic acid to be well tolerated and safe for use in prostate cancer patients, while the studies conducted by Polascik et al [49] and Oh et al [50] would appear to contradict this. The latter two studies, however, were not placebo-controlled.…”

“…The study revealed mean maximal change in serum creatinine (SCr) level from baseline was 0.3 mg/dl (where notable SCr increases is defined as an increase ]0.5 mg/dl for patients with normal baseline SCr levels B1.4 mg/dl, an increase ]1.0 mg/dl for patients with abnormal baseline SCr levels or ]2 times the baseline value) [49]. However, notably increased SCr levels were reported in 47 patients (21.2%) and for 21 (44.6%) of these patients, treatment was discontinued.…”

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates

“…[20][21][22] The results of an open-label study evaluating zoledronic acid in prostate cancer patients with hormone-sensitive metastatic disease showed that zoledronic acid effectively increased BMD and reduced levels of bone metabolism markers in these patients. 29 Furthermore, only 11.9% of these patients developed an SRE, suggesting that zoledronic acid prevents bone complications in patients with both hormone-sensitive and -resistant metastatic disease. 29 The National Comprehensive Cancer Network Guidelines on Prostate Cancer state that early intervention with bisphosphonates in all prostate cancer patients receiving ADT may improve quality of life and prevent morbidity associated with ADT-or metastatic disease-induced bone loss.…”

“…29 Furthermore, only 11.9% of these patients developed an SRE, suggesting that zoledronic acid prevents bone complications in patients with both hormone-sensitive and -resistant metastatic disease. 29 The National Comprehensive Cancer Network Guidelines on Prostate Cancer state that early intervention with bisphosphonates in all prostate cancer patients receiving ADT may improve quality of life and prevent morbidity associated with ADT-or metastatic disease-induced bone loss.…”

Nephrotic syndrome induced by pamidronate

“…Orally administered bisphosphonates are regularly used for the treatment of osteoporosis, whereas hypercalcemia and osteolytic metastases are mainly treated by intravenous administration of bisphosphonates [1][2][3][4]. Pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonate) is one of the most potent intravenously given bisphosphonates.…”